Evidence map›Paper›PMID 42096279›Full record

ReviewEpilepsia2026

Management of ring chromosome 20 syndrome: Narrative review and consensus recommendations.

Asma Khamis, Emilia Ricci, Maria Paola Canevini, Lieven Lagae, Kentaro Tokumoto, Yushi Inoue, Tim Buckinx, Allison Watson, Kenneth A Myers

Abstract readReviewConsensus Statement
In one paragraph

Review in Epilepsia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Asma KhamisFaculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada.ORCID https://orcid.org/0009-0001-8186-0525
Emilia RicciEpilepsy Center, Child Neurology Unit, AAST Santi Paolo Carlo, Milan, Italy.ORCID https://orcid.org/0000-0002-3405-6454
Maria Paola CaneviniEpilepsy Center, Child Neurology Unit, AAST Santi Paolo Carlo, Milan, Italy.ORCID https://orcid.org/0000-0002-2292-4015
Lieven LagaeDepartment Paediatric Neurology, University Hospitals KuLeuven, Childhood Epilepsy Center, Leuven, Belgium.ORCID https://orcid.org/0000-0002-7118-0139
Kentaro TokumotoNational Epilepsy Center, National Hospital Organization Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan.ORCID https://orcid.org/0000-0002-2502-5496
Yushi InoueNational Epilepsy Center, National Hospital Organization Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan.ORCID https://orcid.org/0000-0001-7654-036X
Tim BuckinxRing 20 Research & Support UK CIO, Poole, Dorset, UK.ORCID https://orcid.org/0009-0003-7685-1768
Allison WatsonRing 20 Research & Support UK CIO, Poole, Dorset, UK.ORCID https://orcid.org/0000-0001-7201-9710
Kenneth A MyersChild Health & Human Development Program, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.ORCID https://orcid.org/0000-0001-7831-4593

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ring chromosome 20 (ring 20) is a rare genetic condition usually presenting as developmental and epileptic encephalopathy. The disease is caused by fusion of the long and short arms of chromosome 20. Patients are symptomatic even if there is no loss of genetic material. Epilepsy in ring 20 is usually drug-resistant, with seizures often significantly debilitating and severely impacting quality of life. We assembled a taskforce of clinician-scientists with expertise in ring 20, as well as caregivers of individuals with ring 20. We then reviewed published literature on ring 20 with a focus on management with the aim of developing recommendations for the treatment of this disorder. Our review found that there are very few high-quality data available to guide treatment in ring 20. The majority of publications are individual case reports or small case series. Based on these limited data, as well as personal experience, we recommend the following. (1) The care team should be multidisciplinary and include at least an epileptologist and allied health specialists (e.g., speech therapist, occupational therapist, physiotherapist, psychologist); (2) patients and families should be referred for genetic counseling; (3) if patients are diagnosed with epilepsy, they and their families should be counseled that seizures are likely to be drug-resistant and life-long; (4) as there is a high incidence of non-convulsive status epilepticus (NCSE), there should be a low threshold for video-EEG monitoring if patients have a change in behavior or level of consciousness; (5) initial epilepsy treatment should be with an oral anti-seizure medication; (6) home rescue medication should be considered given the risk for prolonged seizures and NCSE; (7) for patients with drug-resistant epilepsy, ketogenic diet, vagus nerve stimulation, or deep brain stimulation could all be considered; and (8) caregiver burnout and stress should be screened for and supports provided.

Indexed as

EpilepsyChromosomes, Human, Pair 20Genetic CounselingHumansRing Chromosomesdevelopmental and epileptic encephalopathyepilepsynon‐convulsive status epilepticusring chromosomering chromosome 20

Identifiers

PMID42096279
PMCPMC13525565

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.